Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trospium. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 known ✓ | P20309 | 12/20 | 1.00 |
| ▸ | CHRM2 known ✓ | P08172 | 11/20 | 1.00 |
| ▸ | CHRM1 | P11229 | 5/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 2/20 | 1.00 |
| ▸ | CHRM5 | P08912 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 3/20 | 0.97 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 2/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trospium SCHEMBL13836646 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL29389006 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL111738 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL25785 | 1.00 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL119810 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL2447242 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL724191 | 0.99 | CHRM3 (1.00) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL31112961 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL22609933 | 0.97 | CHRM3 (0.97) | CHRM3CHRM2CHRM1CHRM4CHRM5 | |
| Trospium SCHEMBL1707994 | 0.94 | CHRM3 (0.89) | CHRM3CHRM2CHRM1CHRM4CHRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3646870-B1 | COMPOSITIONS FOR TREATMENT OF DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | PureTech Health LLC (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3856182-B1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | KARUNA THERAPEUTICS INC (US) | 2025-12-24 | — | — | EP | claimed |
| EP-3441087-B1 | METHODS OF TREATING CHRONIC PAIN | TEVA PHARMACEUTICALS INT GMBH (CH) | 2025-02-19 | — | — | EP | claimed |
| EP-4126138-B1 | AEROSOL DELIVERY OF AT LEAST TWO LIQUID COMPOSITIONS | INVOX BELGIUM NV (BE) | 2024-10-16 | — | — | EP | claimed |
| CN-117379383-A | Production process of dexrazoxane freeze-dried powder injection | 上海旭东海普药业有限公司 | 2024-01-12 | — | — | CN | claimed |
| EP-3307250-B1 | GLYCOPYRRONIUM FATTY ACID SALTS AND METHODS OF MAKING SAME | QAAM PHARMACEUTICALS LLC (US) | 2022-11-23 | — | — | EP | claimed |
| US-20260118370-A1 | PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION | UNIV LOUISVILLE RES FOUND INC (US) | 2026-04-30 | — | — | US | disclosed |
| EP-4729060-A2 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102350-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | KARUNA THERAPEUTICS INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12558317-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2026-02-24 | — | — | US | disclosed |
| EP-3856182-B1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARNIC RECEPTOR ACTIVATION | KARUNA THERAPEUTICS INC (US) | 2025-12-24 | — | — | EP | disclosed |
| US-12487200-B2 | Microfabricated differential scanning calorimetry system and methods of use thereof | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-12487246-B2 | Plasma thermograms for diagnosis and treatment of acute myocardial infarction | UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, INC. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20230181470-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2023-06-15 | — | — | US | disclosed |
| CN-115581696-A | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | 卡鲁娜治疗学有限公司 | 2023-01-10 | — | — | CN | disclosed |
| US-20220365014-A1 | MICROFABRICATED DIFFERENTIAL SCANNING CALORIMETRY SYSTEM AND METHODS OF USE THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-11-17 | — | — | US | disclosed |
| US-11471413-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2022-10-18 | — | — | US | disclosed |
| US-11452692-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | Karuna Therapeutics, Inc. (US) | 2022-09-27 | — | — | US | disclosed |
| CN-114885599-A | Controlled release formulation delivery device | 因库博实验室有限责任公司 | 2022-08-09 | — | — | CN | disclosed |
| US-20220151933-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | Karuna Therapeutics, Inc. | 2022-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11471413-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | CHRM5, CHRM3, CHRNA5 | CHRM3 2/4885CHRM2 4/4885CHRM1 6/4885 |
| US-11452692-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | CHRM5, CHRM3, CHRNA5 | CHRM3 2/4885CHRM2 4/4885CHRM1 6/4885 |
| US-20260102350-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, TAAR5, MC5R | CHRM3 9/4885CHRM2 8/4885CHRM1 10/4885 |
| US-12558317-B2 | Compositions and methods for treating disorders ameliorated by muscarinic receptor activation | CHRM5, CHRM1, OPRM1 | CHRM3 5/4885CHRM2 4/4885CHRM1 2/4885 |
| US-20260118370-A1 | PLASMA THERMOGRAMS FOR DIAGNOSIS AND TREATMENT OF ACUTE MYOCARDIAL INFARCTION | TNNI3, TNNT2, TNNC1 | CHRM3 1952/4885CHRM2 1903/4885CHRM1 1589/4885 |
| US-20230181470-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, CHRM3, CHRNA5 | CHRM3 2/4885CHRM2 4/4885CHRM1 6/4885 |
| US-20220151933-A1 | COMPOSITIONS AND METHODS FOR TREATING DISORDERS AMELIORATED BY MUSCARINIC RECEPTOR ACTIVATION | CHRM5, CHRM3, CHRNA5 | CHRM3 2/4885CHRM2 4/4885CHRM1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.